title: TNF-α SNP rs1800629 and risk of relapse in childhood acute lymphoblastic leukemia: relation to immunophenotype.
abstract: OBJECTIVE
  In the AIEOP-BFM ALL (Associazione Italiana Ematologia Oncologia Pediatrica-Berlin Frankfurt Münster acute lymphoblastic leukemia) 2000 protocol, 70% of relapsed patients had favorable prognostic features and fell within less intensive polychemotherapeutic regimens, suggesting the need for better assessing lower risk stratification.
  
  
  METHODS
  A novel two-phase study design selected 614 children to be genotyped for TNF-α SNP rs1800629 (-308G>A). A weighted Cox model was applied to evaluate the SNP effect on hazard of relapse, adjusting for immunophenotype, risk group, age and gender and including interaction terms.
  
  
  RESULTS
  Significant interaction was found with immunophenotypes (p = 0.0007, with minor allele genotypes being adverse genetic markers in B-cell acute lymphoblastic leukemia and protective ones in T-cell acute lymphoblastic leukemia), and also with risk protocols (p = 0.0041, with minor allele genotypes as prognostic factor of relapse for standard risk patients [only one T-cell acute lymphoblastic leukemia in the subgroup analyzed]).
  
  
  CONCLUSIONS
  The presence of at least one A allele in TNF-α SNP rs1800629 should suggest a closer monitoring in B-cell acute lymphoblastic leukemia standard risk patients.
authors.affiliation: Institute for Maternal & Child Health (I.R.C.C.S) Burlo Garofolo, UO Pediatric Hemato-Oncology, Via dell'Istria 65/1, 34137 Trieste, Italy.
authors.forename: Raffaella
authors.initials: R
authors.lastname: Franca
authors.forename: Paola
authors.initials: P
authors.lastname: Rebora
authors.forename: Emmanouil
authors.initials: E
authors.lastname: Athanasakis
authors.forename: Diego
authors.initials: D
authors.lastname: Favretto
authors.forename: Federico
authors.initials: F
authors.lastname: Verzegnassi
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Basso
authors.forename: Alberto
authors.initials: A
authors.lastname: Tommasini
authors.forename: Maria Grazia
authors.initials: MG
authors.lastname: Valsecchi
authors.forename: Giuliana
authors.initials: G
authors.lastname: Decorti
authors.forename: Marco
authors.initials: M
authors.lastname: Rabusin
mesh_terms: D000293:Adolescent; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D019008:Drug Resistance, Neoplasm / Q000235:genetics; D005260:Female; D005838:Genotype; D006801:Humans; D007223:Infant; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000235:genetics; D008297:Male; D010641:Phenotype; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000235:genetics* / Q000276:immunology*; D054218:Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / Q000235:genetics; D012008:Recurrence; D018570:Risk Assessment; D013256:Steroids / Q000627:therapeutic use; D014409:Tumor Necrosis Factor-alpha / Q000235:genetics*
chemical_list: D000970:Antineoplastic Agents; D013256:Steroids; D014409:Tumor Necrosis Factor-alpha